Use of Peptides for the Management of Alzheimer's Disease: Diagnosis and Inhibition

• Published in: Frontiers in aging neuroscience Vol. 10; p. 21
• Main Authors: Baig, Mohammad H, Ahmad, Khurshid, Rabbani, Gulam, Choi, Inho
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 07.02.2018; Frontiers Media S.A
• Subjects: Alzheimer's disease; amyloid beta; BACE-1; Biomarkers; Brain research; Clinical trials; Dementia disorders; Diagnosis; Disease; GAPDH; Glyceraldehyde-3-phosphate dehydrogenase; Hypotheses; inhibitors; Ligands; Neurodegenerative diseases; Neurons; Neuroscience; NMR; Nuclear magnetic resonance; Peptides; Potassium channels (voltage-gated); Protein-tyrosine-phosphatase; Proteins; β-Site APP-cleaving enzyme 1; inhibitors; Alzheimer’s disease; BACE-1; diagnosis; peptides; GAPDH; amyloid beta
• ISSN: 1663-4365; 1663-4365
• DOI: 10.3389/fnagi.2018.00021

Alzheimer's disease (AD) is a form of dementia and the most common progressive neurodegenerative disease (ND). The targeting of amyloid-beta (Aβ) aggregation is one of the most widely used strategies to manage AD, and efforts are being made globally to develop peptide-based compounds for the early diagnosis and treatment of AD. Here, we briefly discuss the use of peptide-based compounds for the early diagnosis and treatment of AD and the use of peptide-based inhibitors targeting various Aβ aggregation checkpoints. In addition, we briefly discuss recent applications of peptide-based inhibitors against various AD targets including amyloid beta, β-site amyloid precursor protein cleaving enzyme 1 (BACE1), Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), tyrosine phosphatase (TP) and potassium channel KV1.3.